What does Oostpharma do?

Oostpharma is a pharmacy in Assenede. Private Limited, started on 16 December 2003, 1 establishment.

What is the address of Oostpharma?

The registered office of Oostpharma is located at Oosteeklo-Dorp 6, 9968 Assenede.

Is Oostpharma still active?

Yes. According to the CBE (30 October 2026) Oostpharma is active, legal situation “Normale toestand”, started on 16 December 2003.

Is Oostpharma registered on Peppol?

Yes, Oostpharma is registered on the Peppol network with ID 0208:0862223003.

What is the enterprise number of Oostpharma?

The enterprise number of Oostpharma is BE0862223003.

When was Oostpharma founded?

Oostpharma was founded on 16 December 2003.

Who are the directors of Oostpharma?

According to the 2025 annual accounts, the directors of Oostpharma are: Gavic Investments BV.

Is Oostpharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 December 2003; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Oostpharma make in 2025?

Oostpharma posted a profit after taxes of € 50,468 in financial year 2025.

What is the revenue of Oostpharma?

As a small company, Oostpharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 146,732.

How much does an employee at Oostpharma earn?

The average wage cost per full-time employee at Oostpharma was € 40,000 in 2025: staff costs of € 39,961 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Oostpharma have?

According to the 2025 annual accounts, Oostpharma has 1 full-time equivalents (FTE).

Oostpharma (Private Limited) - Assenede - BE0862223003

Dossier Oostpharma, printed on 30 October 2026 from databakkes.be/en/0862223003/oostpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 59 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Oostpharma from Assenede, company number BE0862223003, closed financial year 2025 with a result of € 50,468 after tax. For that financial year Oostpharma recorded a gross margin of € 146,732 and equity of € 243,303. Compared with financial year 2024, the result moved from € 39,328 to € 50,468. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.

What it is worth Growing

€ 243,303

▲ 26% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 50,468

▲ 28% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 67,613

▼ 36% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 224,703.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 39,961

▲ 51% vs 2024

€ 40,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 993

▼ 49% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 11 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 119,962

▼ 16% vs 2024

€ 10,942 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.

Owed to suppliers

€ 37,877

▼ 26% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 17,682

▲ 130% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 142,928 Gross margin 2022: € 142,928 First fiscal year in the series	€ 134,381 Gross margin 2023: € 134,381 ▼ 6% vs 2022 (€ 142,928) Unfavourable step	€ 114,753 Gross margin 2024: € 114,753 ▼ 15% vs 2023 (€ 134,381) Unfavourable step	€ 146,732 Gross margin 2025: € 146,732 ▲ 28% vs 2024 (€ 114,753) Favourable step	▲ 28%
Profit after taxes	€ 74,508 Profit after taxes 2022: € 74,508 First fiscal year in the series	€ 50,025 Profit after taxes 2023: € 50,025 ▼ 33% vs 2022 (€ 74,508) Unfavourable step	€ 39,328 Profit after taxes 2024: € 39,328 ▼ 21% vs 2023 (€ 50,025) Unfavourable step	€ 50,468 Profit after taxes 2025: € 50,468 ▲ 28% vs 2024 (€ 39,328) Favourable step	▲ 28%
Equity	€ 378,482 Equity 2022: € 378,482 First fiscal year in the series	€ 403,506 Equity 2023: € 403,506 ▲ 7% vs 2022 (€ 378,482) Favourable step	€ 192,835 Equity 2024: € 192,835 ▼ 52% vs 2023 (€ 403,506) Unfavourable step	€ 243,303 Equity 2025: € 243,303 ▲ 26% vs 2024 (€ 192,835) Favourable step	▲ 26%
Total debts	€ 341,122 Total debts 2022: € 341,122 First fiscal year in the series	€ 289,885 Total debts 2023: € 289,885 ▼ 15% vs 2022 (€ 341,122) Favourable step	€ 459,327 Total debts 2024: € 459,327 ▲ 58% vs 2023 (€ 289,885) Unfavourable step	€ 383,749 Total debts 2025: € 383,749 ▼ 16% vs 2024 (€ 459,327) Favourable step	▼ 16%
Cash	€ 67,960 Cash 2022: € 67,960 First fiscal year in the series	€ 40,650 Cash 2023: € 40,650 ▼ 40% vs 2022 (€ 67,960) Unfavourable step	€ 106,010 Cash 2024: € 106,010 ▲ 161% vs 2023 (€ 40,650) Favourable step	€ 67,613 Cash 2025: € 67,613 ▼ 36% vs 2024 (€ 106,010) Unfavourable step	▼ 36%
Land & buildings	€ 320,243 Land & buildings 2022: € 320,243 First fiscal year in the series	€ 298,339 Land & buildings 2023: € 298,339 ▼ 7% vs 2022 (€ 320,243) Unchanged	€ 276,453 Land & buildings 2024: € 276,453 ▼ 7% vs 2023 (€ 298,339) Unchanged	€ 254,759 Land & buildings 2025: € 254,759 ▼ 8% vs 2024 (€ 276,453) Unchanged	▼ 8%
Retained profit	€ 359,882 Retained profit 2022: € 359,882 First fiscal year in the series	€ 384,906 Retained profit 2023: € 384,906 ▲ 7% vs 2022 (€ 359,882) Favourable step	€ 174,235 Retained profit 2024: € 174,235 ▼ 55% vs 2023 (€ 384,906) Unfavourable step	€ 224,703 Retained profit 2025: € 224,703 ▲ 29% vs 2024 (€ 174,235) Favourable step	▲ 29%
Dividend	€ 40,000 Dividend 2022: € 40,000 First fiscal year in the series	€ 25,000 Dividend 2023: € 25,000 ▼ 37% vs 2022 (€ 40,000) Unchanged	€ 250,000 Dividend 2024: € 250,000 ▲ € 225,000 vs 2023 (€ 25,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 250,000) Unchanged	▼ 100%
Bank debt	€ 199,417 Bank debt 2022: € 199,417 First fiscal year in the series	€ 170,561 Bank debt 2023: € 170,561 ▼ 14% vs 2022 (€ 199,417) Favourable step	€ 142,291 Bank debt 2024: € 142,291 ▼ 17% vs 2023 (€ 170,561) Favourable step	€ 119,962 Bank debt 2025: € 119,962 ▼ 16% vs 2024 (€ 142,291) Favourable step	▼ 16%
Balance sheet total	€ 719,604 Balance sheet total 2022: € 719,604 First fiscal year in the series	€ 693,391 Balance sheet total 2023: € 693,391 ▼ 4% vs 2022 (€ 719,604) Unchanged	€ 652,162 Balance sheet total 2024: € 652,162 ▼ 6% vs 2023 (€ 693,391) Unchanged	€ 627,051 Balance sheet total 2025: € 627,051 ▼ 4% vs 2024 (€ 652,162) Unchanged	▼ 4%
Employees (FTE)	0.5 Employees (FTE) 2022: 0.5 First fiscal year in the series	1.1 Employees (FTE) 2023: 1.1 ▲ 0.6 vs 2022 (0.5) Unchanged	1 Employees (FTE) 2024: 1 ▼ 0.1 vs 2023 (1.1) Unchanged	1 Employees (FTE) 2025: 1 Unchanged (1) Unchanged

Key figures of Oostpharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Oostpharma?

What happened at Oostpharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 10, 2026 New annual accounts for financial year 2025: profit of € 50,468 (▲ 28% vs 2024). Source: NBB ↗
Feb 1, 2004 New establishment in Assenede. KBO
Dec 16, 2003 Start of the company according to the CBE. KBO

In short

From € 74,508 profit in 2022 to € 50,468 profit in 2025.

Paid € 51,556 in corporate taxes since 2022.

Best year ever: 2022, with € 74,508 profit.

On average € 146,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

GAVIC INVESTMENTS 100%

The stake of GAVIC INVESTMENTS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Oostpharma

Behind Oostpharma is Gavic Investments BV. The shares are held by GAVIC INVESTMENTS (100%).

Directors

According to the 2025 annual accounts

Gavic Investments BV

Director · represented by Ann-Rose De Pauw

Shareholders

GAVIC INVESTMENTS

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Oosteeklo-Dorp 6

9968 Assenede

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

GAVIC INVESTMENTS same network

€ 200,476 gross margin · 2025

GAVIC VAT

Bike Import

€ -1,925 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0862.223.003

VAT number

BE 0862.223.003

Registered office

Oosteeklo-Dorp 6, 9968 Assenede

Names & denominations

Oostpharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

16 December 2003

Peppol

Active · Active since 22 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

Oostpharma

Warning lights

Financials

What happened to Oostpharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions